MUKUND K SHAH M.D.
Prescription History 1194829721
Internal Medicine - Hematology & Oncology in Marietta, OH


Quality Rating: 94.1 out of 100 score

NPI Status: Active since September 12, 2006

Contact Information

400 MATTHEW ST
STRECKER CANCER CENTER
MARIETTA, OH
ZIP 45750
Phone: (740) 376-5000
Fax: (740) 376-5002

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MUKUND K SHAH M.D., an active Hematology & Oncology specialist practicing in Marietta, OH. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 172 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 85 claims alone.

Medication Index


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 71.7
Days Supply 2,131
OH State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills95.8
Peer Average Days Supply2,823
Conservative Utilization

This provider writes prescriptions for this formulation 28.9% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $403.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.61

State Avg Cost Per Claim

$10.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 85
30-Day Fills 187.2
Days Supply 5,566
OH State Average Benchmarks
Peer Average Claims75.0
Peer Average 30-Day Fills168.5
Peer Average Days Supply5,019
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,975.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.24

State Avg Cost Per Claim

$26.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 40.9
Days Supply 1,217
OH State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills67.0
Peer Average Days Supply1,982
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $223.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.39

State Avg Cost Per Claim

$38.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
OH State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.1
Peer Average Days Supply685
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,419.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,492.72

State Avg Cost Per Claim

$2,905.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
OH State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply1,030
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.9% less volume than the regional standard for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $203,553.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,657.97

State Avg Cost Per Claim

$14,964.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.0
Days Supply 485
OH State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills61.0
Peer Average Days Supply1,076
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.5% less volume than the regional standard for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $81.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.28

State Avg Cost Per Claim

$5.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MUKUND K SHAH M.D. provides transparency into local medical care patterns within Marietta, OH.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.